Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

Akihiro Funakoshi, Hikoyuki Horiuchi, Terufumi Sakai, Toshihiko Miyahara, Toru Muranaka, Masashi Nakamura, Kazuhiro Mizumoto, Toshiharu Ueki, Akinobu Taketomi, Hiroya Yamaguchi, Toshihiko Sumii, Tetsuhide Ito

Research output: Contribution to journalArticle

Abstract

There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

Original languageEnglish
Pages (from-to)2875-2879
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number13
Publication statusPublished - Dec 2010

Fingerprint

Biliary Tract Neoplasms
Drug Therapy
Survival
gemcitabine
Age Groups
Clinical Trials
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Funakoshi, A., Horiuchi, H., Sakai, T., Miyahara, T., Muranaka, T., Nakamura, M., ... Ito, T. (2010). Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis. Japanese Journal of Cancer and Chemotherapy, 37(13), 2875-2879.

Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis. / Funakoshi, Akihiro; Horiuchi, Hikoyuki; Sakai, Terufumi; Miyahara, Toshihiko; Muranaka, Toru; Nakamura, Masashi; Mizumoto, Kazuhiro; Ueki, Toshiharu; Taketomi, Akinobu; Yamaguchi, Hiroya; Sumii, Toshihiko; Ito, Tetsuhide.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 37, No. 13, 12.2010, p. 2875-2879.

Research output: Contribution to journalArticle

Funakoshi, A, Horiuchi, H, Sakai, T, Miyahara, T, Muranaka, T, Nakamura, M, Mizumoto, K, Ueki, T, Taketomi, A, Yamaguchi, H, Sumii, T & Ito, T 2010, 'Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis', Japanese Journal of Cancer and Chemotherapy, vol. 37, no. 13, pp. 2875-2879.
Funakoshi A, Horiuchi H, Sakai T, Miyahara T, Muranaka T, Nakamura M et al. Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis. Japanese Journal of Cancer and Chemotherapy. 2010 Dec;37(13):2875-2879.
Funakoshi, Akihiro ; Horiuchi, Hikoyuki ; Sakai, Terufumi ; Miyahara, Toshihiko ; Muranaka, Toru ; Nakamura, Masashi ; Mizumoto, Kazuhiro ; Ueki, Toshiharu ; Taketomi, Akinobu ; Yamaguchi, Hiroya ; Sumii, Toshihiko ; Ito, Tetsuhide. / Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis. In: Japanese Journal of Cancer and Chemotherapy. 2010 ; Vol. 37, No. 13. pp. 2875-2879.
@article{9451e6fbfa8a4e119e5acfefc93b9348,
title = "Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis",
abstract = "There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.",
author = "Akihiro Funakoshi and Hikoyuki Horiuchi and Terufumi Sakai and Toshihiko Miyahara and Toru Muranaka and Masashi Nakamura and Kazuhiro Mizumoto and Toshiharu Ueki and Akinobu Taketomi and Hiroya Yamaguchi and Toshihiko Sumii and Tetsuhide Ito",
year = "2010",
month = "12",
language = "English",
volume = "37",
pages = "2875--2879",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

AU - Funakoshi, Akihiro

AU - Horiuchi, Hikoyuki

AU - Sakai, Terufumi

AU - Miyahara, Toshihiko

AU - Muranaka, Toru

AU - Nakamura, Masashi

AU - Mizumoto, Kazuhiro

AU - Ueki, Toshiharu

AU - Taketomi, Akinobu

AU - Yamaguchi, Hiroya

AU - Sumii, Toshihiko

AU - Ito, Tetsuhide

PY - 2010/12

Y1 - 2010/12

N2 - There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

AB - There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

UR - http://www.scopus.com/inward/record.url?scp=79960964692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960964692&partnerID=8YFLogxK

M3 - Article

C2 - 21160263

AN - SCOPUS:79960964692

VL - 37

SP - 2875

EP - 2879

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -